Dafinchiit is Roopal. So on the CD subcutaneous SKYRIZI, as I highlighted, very strong data. It is with SKYRIZI, so it is a asset well known, to health authorities. And manufacturing is very well known to us.
ABBV2026 Q2Healthcare
1mo
AbbVie Inc. 2026 Q2: Financial Performance summary
Financial Performance Summary
- Adjusted EPS was $3.65 in Q2, $0.06 above the guidance midpoint.
- Adjusted gross margin was 84.7% of sales; adjusted R&D expense was 13.6% of sales; adjusted SG&A was 21% of sales.
- Adjusted operating margin was 48.3% of sales, including a 1.7% unfavorable impact from acquired IPR&D expense.
- Immunology segment performance: total revenues nearly $8.8 billion, up 14.6% operationally.
- Neuroscience segment performance: total revenues more than $3.2 billion, up approximately 20% operationally.
- Oncology segment performance: total revenues more than $1.6 billion, down 2.4% operationally; VENCLEXTA sales were $771 million up 9.6% operationally.
- Total net revenues were nearly $17 billion, beating expectations by $300 million and up 10.2% year over year (with a 0.7% favorable FX impact mentioned).